Cargando…
Erenumab: A novel calcitonin gene-related peptide receptor antagonist developed specifically for migraine prevention
Headaches and migraines continue to be a leading cause of suffering and disability. As per the Global Burden of Disease Survey conducted in 2010, the exact magnitude of the disease still is underestimated. Migraine alone continues to rank seventh as a cause of disability. Various therapeutic modalit...
Autores principales: | Garg, Shuchita, Vij, Malti, Edward, Neeraj, Vij, Brinder |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7047699/ https://www.ncbi.nlm.nih.gov/pubmed/32174669 http://dx.doi.org/10.4103/joacp.JOACP_3_19 |
Ejemplares similares
-
Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine
por: Xu, Fang, et al.
Publicado: (2019) -
Migraine induction with calcitonin gene-related peptide in patients from erenumab trials
por: Christensen, Casper Emil, et al.
Publicado: (2018) -
Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab
por: Giamberardino, Maria Adele, et al.
Publicado: (2017) -
A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene‐related peptide ligand (galcanezumab) or receptor (erenumab) antagonist
por: Kudrow, David, et al.
Publicado: (2022) -
Vascular safety of erenumab for migraine prevention
por: Kudrow, David, et al.
Publicado: (2020)